Americans who fill prescriptions through Canadian and other international mail-order pharmacies have about three weeks before a federal customs rule reaches its compliance deadline on October 22, and a growing number of members of Congress are urging the Trump administration to reconsider it. The rule, issued by U.S. Customs and Border Protection (CBP), does not name any drug or ban prescriptions outright. But it could make routine personal shipments far harder and costlier to deliver, STAT reported.
For many households, this is a budget issue first. People who order insulin, inhalers, blood thinners, or cancer drugs from abroad usually do so because the same medicine costs much more at a U.S. pharmacy. If shipments stall, patients could face gaps in treatment or a sudden jump in monthly costs.
A 2020 study in JAMA Network Open, based on 2015 to 2017 national survey data, estimated that about 2.3 million U.S. adults bought prescription drugs from other countries to save money. Older adults on fixed incomes are among those most exposed if a lower-cost supply line closes with little warning.
A Paperwork Change with Consequences for Personal Orders
The rule was published in the Federal Register on June 24. It indefinitely suspends the de minimis exemption that let packages worth $800 or less arrive by international mail without formal customs paperwork. It also creates a new postal entry process for shipments worth up to $2,500 and requires an entry bond. Most provisions took effect July 24, but the compliance date for goods regulated by partner agencies, a category that includes products under FDA oversight, is October 22.
The rule text does not specifically address prescription drugs or personal-use medicines, which is why its practical impact remains uncertain. STAT reported that, in practice, medicines mailed from abroad would have to go through a customs process that requires a licensed customs broker and a financial guarantee known as an entry bond, adding cost and complexity for small personal orders.
The Canadian International Pharmacy Association, which represents licensed Canadian pharmacies that ship to U.S. patients, has taken the most pessimistic view. “Unless those arrangements change, Americans should expect that virtually all routine personal prescription orders mailed from licensed Canadian and international pharmacies will be unable to reach them,” the group said in a public statement on the new requirements. That is the group’s prediction, not a finding by CBP.
MedicalDaily could not confirm which lawmakers are behind the push, or whether CBP plans to delay the October 22 date or carve out personal prescriptions.
The Legal Gray Zone Patients Have Relied On
Importing prescription drugs for personal use has technically been illegal in most cases for decades, because foreign versions are usually not FDA-approved. The FDA has long used enforcement discretion and, under its personal importation guidance, may allow some shipments when the quantity is generally no more than a three-month supply. The customs change does not rewrite drug law. It changes how easily those packages move through the mail.
PharmacyChecker, which verifies online pharmacies, has asked the FDA to keep a risk-based approach for personal shipments. President Lucia Mueller said in a statement urging the FDA that more border data should help the agency tell “your daughter’s inhalers or your neighbor’s insulin” apart from shipments that pose a genuine public health threat.
Patients most likely to feel the effects include older adults paying cash for brand-name drugs, uninsured adults, and people taking expensive maintenance medicines for diabetes, asthma, heart conditions, or cancer. Anyone who depends on a single foreign supplier with no backup plan faces the greatest risk of a gap in therapy.
Steps to Take Before the Deadline
The most important step is to avoid running out. Patients who order from abroad can check how many days of medicine they have on hand and ask their foreign pharmacy, in writing, how it plans to ship after October 22 and what refund policy applies if a package is held. Stockpiling a large supply is not a safe fix, since drugs expire and larger orders can draw more scrutiny.
Talk with the prescribing clinician now about a backup. Ask whether a lower-cost U.S. generic, a different drug in the same class, or a manufacturer patient assistance program could cover the gap.
Many drugmakers offer free or discounted medicine to people who qualify by income. U.S. pharmacy cash prices also vary widely, so comparing several pharmacies can reveal savings.
People on Medicare have another option coming up. Open enrollment for 2027 coverage runs October 15 to December 7. The Part D out-of-pocket drug cost cap is $2,100 in 2026 and rises to $2,400 in 2027. Reviewing plans during that window may lower costs for some patients who have been buying abroad.
Do not stop taking a prescribed medicine or change doses without speaking to a clinician. Stopping insulin, blood thinners, seizure drugs, or heart medicines suddenly can be dangerous. Anyone who runs out and develops symptoms such as chest pain, trouble breathing, or very high blood sugar should seek urgent care.
Readers should watch for any CBP guidance on personal-use prescriptions, any FDA statement on enforcement, and whether the October 22 compliance date holds. MedicalDaily will update this story as agencies respond.
The rule may not end every personal import, but patients relying on mail from Canada should line up a backup source and talk to their doctor before late October.